Plain-English translation of NCT06334133 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Diabetes Mellitus, Type 1 research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing a medication called cadisegliatin to see if it can help people with type 1 diabetes avoid dangerous drops in blood sugar while they continue taking their regular insulin. Researchers want to understand whether this new treatment, given in addition to insulin, can reduce how often participants experience low blood sugar episodes. The study will compare cadisegliatin at different doses to a placebo (a dummy pill with no active ingredient) over 26 weeks.
Many people with type 1 diabetes struggle with unpredictable low blood sugar episodes that can be scary and harmful. This medication is being tested to see if it can help prevent these dangerous lows and give patients more stable, safer blood sugar control.
Over about 4 months total, you would attend screening visits and a training period where researchers help adjust your insulin and teach you about the study devices. Then you would take either the new medication or a placebo pill twice daily (or once daily, depending on which group you're assigned to) for 26 weeks while continuing your regular insulin therapy. You would continue wearing your glucose monitor and keep using your insulin pump or injections as normal. Researchers will track your blood sugar readings and check how many low blood sugar episodes you experience during the treatment period.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States